1Colomo L, Lopez-Guillermo A, Perales M, et al. Clinical impact of the differentiation profile assessed by immunophenotying in patients with diffuse large B-cell lymphoma. Blood,2003,101: 78-84.
2Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Engl J Med,2002, 346:235-242.
3Barrans SL, Carter Ⅰ, Owen RG, et al. Germinal center phenotype and expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma. Blood,2002,99:1136-1143.
4Koniaris LG, Drugas G, Katzman P J, et al. Management of gastrointestinal lymphoma. J Am Coll Surg,2003,197:127-141.
5Ibrabin EM, Ezzat AA, EI-Weshi AN, et al. Primary intestinal diffuse large B-cell non-Hodgkin's lymphoma: clinical features, management,and progrosis of 66 patients. Ann Oncol,2001,12:53-58.
6Michael MB, Christensen BE, Petersan NT, et al. Prognosis of localized diffuse large B-cell lymphoma in younger patients. Cancer, 2003, 98:516-521.
7Wilder KB, Rodriguez MA, Medeiros LJ, et al. International prognostic index-based outcomes for diffuse large B-cell lymphomas. Cancer,2002,94: 3083-3088.
8Harris NL, Jaffe ES, Diebold J, et al. World-Health Organization classification of neoplastic disease of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting. J Clin Oncol,1999,17: 3835-3849.
9Harris NL, Jaffe ES, Stein H, et al. A revised Europenn-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood, 1994, 84: 1361-1392.
10Diebold J, Anderson JR, Armitage JO, et al. Diffuse large B-cell lymphoma: a clinicopathologic analysis of 444 cases classified according to the updated Kiel classification. Leuk Lymphoma, 2002,43:97-104.
2Markowski J,Kajor M,Gierek T,et al.[Histologic and clinical assessment of primary extranodal non-Hodgkin malignant lymphomas of the head and neck region] [J].Otolaryngol Pol,2004,58(3):429-435.
